Nuo Therapeutics Inc
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospita… Read more
Nuo Therapeutics Inc (AURX) - Total Assets
Latest total assets as of June 2025: $1.36 Million USD
Based on the latest financial reports, Nuo Therapeutics Inc (AURX) holds total assets worth $1.36 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nuo Therapeutics Inc - Total Assets Trend (2014–2024)
This chart illustrates how Nuo Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nuo Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Nuo Therapeutics Inc's total assets of $1.36 Million consist of 70.8% current assets and 29.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.9% |
| Accounts Receivable | $248.21K | 20.9% |
| Inventory | $150.44K | 12.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Nuo Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nuo Therapeutics Inc's current assets represent 70.8% of total assets in 2024, an increase from 38.1% in 2014.
- Cash Position: Cash and equivalents constituted 23.9% of total assets in 2024, down from 28.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 53.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 20.9% of total assets.
Nuo Therapeutics Inc Competitors by Total Assets
Key competitors of Nuo Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Nuo Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Nuo Therapeutics Inc generates 1.15x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nuo Therapeutics Inc is currently not profitable relative to its asset base.
Nuo Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.85 | 1.70 | 0.82 |
| Quick Ratio | 0.69 | 1.39 | 0.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-145.68K | $ 484.18K | $ -190.80K |
Nuo Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Nuo Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 41.78 |
| Latest Market Cap to Assets Ratio | 25.55 |
| Asset Growth Rate (YoY) | -36.7% |
| Total Assets | $1.19 Million |
| Market Capitalization | $30.39 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nuo Therapeutics Inc's assets at a significant premium ( 25.55x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Nuo Therapeutics Inc's assets decreased by 36.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nuo Therapeutics Inc (2014–2024)
The table below shows the annual total assets of Nuo Therapeutics Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.19 Million | -36.66% |
| 2023-12-31 | $1.88 Million | -38.38% |
| 2022-12-31 | $3.05 Million | +1932.52% |
| 2021-12-31 | $149.93K | -2.06% |
| 2020-12-31 | $153.09K | -2.66% |
| 2019-12-31 | $157.26K | -83.88% |
| 2018-12-31 | $975.50K | -31.50% |
| 2017-12-31 | $1.42 Million | -89.87% |
| 2016-12-31 | $14.06 Million | +98.72% |
| 2015-12-31 | $7.07 Million | -87.42% |
| 2014-12-31 | $56.22 Million | -- |